Major Fraud Lawsuits Target Regencell Bioscience and SES AI Over Misled Investors
New York, Tuesday, 28 April 2026.
Top law firms are launching major fraud lawsuits against Regencell and SES AI, exposing alleged market manipulation and exaggerated corporate capabilities that cost investors significant financial losses.
The Case Against Regencell Bioscience
On April 27, 2026, prominent shareholder rights litigators, including the Schall Law Firm and the Rosen Law Firm, announced the filing of securities fraud class action lawsuits against Regencell Bioscience Holdings Limited (NASDAQ: RGC) [1][2]. The complaints allege that between October 28, 2024, and October 31, 2025, Regencell made materially false and misleading statements to the public [1][2]. Specifically, the lawsuits claim the company was highly vulnerable to market manipulation, which exposed investors to severe financial risks and heightened the probability of regulatory and governmental scrutiny [2].
SES AI’s Questionable Partnerships
Parallel to the Regencell litigation, SES AI Corporation (NYSE: SES) is facing its own intense legal scrutiny. The Schall Law Firm and the Rosen Law Firm issued press releases on April 27, 2026, detailing class action lawsuits against the artificial intelligence battery firm [3][6]. The core of the complaint against SES AI revolves around the company’s proprietary Molecular Universe platform [3].
Broader Market Scrutiny: ImmunityBio and Beyond
This wave of litigation extends beyond Regencell and SES AI, reflecting a broader trend of rigorous corporate governance enforcement in the bioscience and technology sectors [GPT]. For instance, the Rosen Law Firm also announced a securities class action against ImmunityBio, Inc. (NASDAQ: IBRX) on April 27, 2026 [5]. The lawsuit alleges that defendants, including prominent executive Patrick Soon-Shiong, materially overstated the capabilities of the company’s Anktiva product, rendering statements about ImmunityBio’s business and prospects materially false [5].
Navigating Lead Plaintiff Deadlines
For investors caught in these volatile equities, understanding the procedural mechanics of class action lawsuits is critical to recovering capital [GPT]. Currently, none of the classes against Regencell, SES AI, or ImmunityBio have been certified by a judge [1][3][5]. Until certification occurs, absent class members are not represented by counsel unless they proactively retain one, though their ability to share in any future recovery does not depend on serving as lead plaintiff [2][3][5].